Comparison

Human C5 Monoclonal Antibody European Partner

Item no. YR0002-20mg
Manufacturer Abclonal
Amount 20 mg
Quantity options 1 mg 20 mg 5 mg
Category
Applications ELISA, FA, NT
Specific against other
Isotype IgG
Purity 89.8% Determined by SDS-PAGE
NCBI C5
Alias C5D,C5a,C5b,ECLZB,CPAMD4
Available
Manufacturer - Applications
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways
Manufacturer - Category
Biosimilar
Manufacturer - Conjugate / Tag
<5% Determined by SECP
Storage Conditions
2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)
Background
Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.The complement immune system destroys and removes foreign particles by the complement cascade triggered by foreign particles. The complement proteins activiated in order create holes or pores in the invading organisms, leading to their destruction. The complement immune system in patients can also destroy healthy cells and tissue, resulting in excessive destruction of red blood cells (hemolysis) or abnormal blood clots to form in small blood vessels throughout the body.When activated, C5 at a late stage in the complement cascade is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a (a potent anaphylatoxin with prothrombotic and proinflammatory properties) and C5b by the C5 convertase, preventing the generation of the terminal complement complex C5b-9 (which also has prothrombotic and proinflammatory effects). Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. By doing so, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.
Manufacturer - Cross Reactivity
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Immunogen
Human C5
Recommended Dilution
In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody
Route
1×PBS pH 7.0
Manufacturer - Research Area
Cancer immunology
Gene Symbol
C5

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 20 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close